Silo Pharma, Inc. SILO
1.75
0.00
0.00%
as of 25 Sep
- Market cap
- $2.8M
- P/E
- 0.0×
Follow SILO
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(86.11%) | (74.56%) | (99.94%) | (91.23%) | |
| (67.91%) | (56.30%) | (74.98%) | (70.96%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(93.05%) | (62.75%) | (79.41%) | (96.21%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(7.71) | (8.34) | (4.15) | (3.57) | |
Free Cash Flow |
(4.80) | (4.66) | (3.80) | (3.92) | |
Capital Expenditures |
— | — | 0.05 | (0.58) | |
Piotroski F-Score |
3.00 | 3.00 | 2.00 | — | |
| Other line items | |||||
Cash ROIC |
(44.12%) | (35.41%) | (32.81%) | (33.03%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.03 | 0.04 | 0.07 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
9,214.80 | 4,752.40 | 3,631.06 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4,158.75% | 3,001.11% | 3,583.47% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
3,278.06% | 2,982.92% | 3,069.03% | 0.00% | |
Share Based Compensation of Revenue |
817.36% | 884.17% | 1,952.50% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.95 | 1.10 | 0.79 | 0.75 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 1.19 | (5.75) | |
Revenue per Share |
0.12 | 0.13 | 0.08 | 0.00 | |
Operating CF per Share |
(7.71) | (8.34) | (4.20) | (3.04) | |
Capex per Share |
0.00 | 0.00 | 0.05 | (0.53) | |
Capex to Sales |
0.00 | 0.00 | (0.63) | 0.00 | |
Net Profit Margin |
(7,050.97%) | (5,871.67%) | (6,726.81%) | 0.00% |
Columns are period end dates